Drugs.com - Pharma Industry News

Durable Disease Control Possible After Stopping Immune Checkpoint Inhibitors in NSCLC

TUESDAY, April 22, 2025 -- Prolonged disease control can be maintained for patients with advanced non-small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors (ICIs) for immune-related adverse events (irAEs), according to a study...

Apr 22, 2025 - 18:06
 0
Durable Disease Control Possible After Stopping Immune Checkpoint Inhibitors in NSCLC
TUESDAY, April 22, 2025 -- Prolonged disease control can be maintained for patients with advanced non-small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors (ICIs) for immune-related adverse events (irAEs), according to a study...
Read More

Tags:

Previous Article

Biolinq raises $100M to carry glucose sensor patch across the finish line

Next Article

Dual-Use of Cigarettes, E-Cigarettes Tied to Same Toxicant Exposure as Cigarette...

Related Posts

Antibiotic Noninferior to Ceftriaxone + Azithromycin for Gonorrhea

Antibiotic Noninferior to Ceftriaxone + Azithromycin fo...

Apr 21, 2025  0

Adoption of Telemedicine Cuts Greenhouse Gas Emissions

Adoption of Telemedicine Cuts Greenhouse Gas Emissions

May 1, 2025  0

Cold Hypersensitivity, Heavy Leg Sensation Tied to Risk for Varicose Veins

Cold Hypersensitivity, Heavy Leg Sensation Tied to Risk...

Apr 24, 2025  0